DP13 - A Phase II Study in Patients With Primary Aldosteronism
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The purpose of the present phase II study is to determine whether DP13 displays the clinical
safety and efficacy profile to support further development in patients with primary
aldosteronism.